Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Regulation01:25

Drug Regulation

1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

162
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
162
Drug Nomenclature01:17

Drug Nomenclature

1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

173
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
173

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Navepegritide: First Approval.

Drugs·2026
Same author

Pixavir Marboxil: First Approval.

Drugs·2026
Same author

Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Correction: Donanemab: First Approval.

Drugs·2024
Same author

Donanemab: First Approval.

Drugs·2024
Same author

Sotatercept: First Approval.

Drugs·2024

相关实验视频

Updated: Jun 29, 2025

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery
06:03

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery

Published on: September 30, 2021

4.7K

丹尼科潘:首次获得批准

Connie Kang1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|March 26, 2024
PubMed
概括
此摘要是机器生成的。

丹尼科潘是一种新型的补充因子D抑制剂,提供了一种新的口服补充疗法,用于 Paroxysmal 夜间血红蛋白尿症 (PNH). 它解决了用C5抑制剂治疗的患者的残留血液溶解,标志着PNH管理的重大进展.

更多相关视频

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.1K
Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis
04:01

Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis

Published on: September 8, 2022

2.4K

相关实验视频

Last Updated: Jun 29, 2025

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery
06:03

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery

Published on: September 30, 2021

4.7K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.1K
Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis
04:01

Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis

Published on: September 8, 2022

2.4K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 血液学 血液学 血液学
  • 罕见疾病 罕见疾病

背景情况:

  • 透性夜间血红蛋白尿 (PNH) 是一种罕见的,获得的血液疾病,其特征是补充介导的血管内和血管外血解.
  • 目前的治疗方法,如C5抑制剂 (eculizumab,ravulizumab) 准终端补充剂,但有些患者会出现残留的血液溶解性贫血.
  • 由替代补充路径驱动的血管外血解仍然是PNH的治疗挑战.

研究的目的:

  • 总结一下danicopan的发展里程碑,danicopan是一种口服补充因子D抑制剂.
  • 要强调danicopan在日本和欧洲作为PNH的附加治疗的监管批准.
  • 讨论丹尼科潘在治疗PNH患者残留血液溶解性贫血的临床意义.

主要方法:

  • 对danicopan.com的临床开发数据和监管提交的审查.
  • 分析丹尼科潘作为补充因子D抑制剂的作用机制.
  • 临床试验结果的摘要证明了PNH患者的疗效和安全性.

主要成果:

  • 丹尼科潘在日本获得批准,用于接受C5抑制剂治疗的PNH成年人.
  • 欧洲药品管理局建议在残留血液溶解性贫血的PNH中授权danicopan的营销.
  • 丹尼科潘在减少外血管血液溶解和改善PNH患者贫血方面表现出有效性.

结论:

  • 丹尼科潘代表了残留血液溶解PNH患者的显著治疗进步.
  • 它的开发和批准提供了一个新的口服治疗选择,针对替代补充途径.
  • 丹尼科潘的附加策略解决了PNH管理的未满足需求,改善了患者的治疗结果.